FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Davidson Matt						2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]									all app Direct Office	er (give title	g Perso	10% O	wner (specify
(Last) (First) (Middle) C/O VERRICA PHARMACEUTICALS INC. 10 NORTH HIGH STREET, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 03/27/2019									belov	w)		below)	
(Street) WEST CHESTER PA 19380 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)						Execution Date,						es Acquired (A) o Of (D) (Instr. 3, 4 a		and 5) Securi Benefi		cially d Following	6. Own Form: (D) or I (I) (Inst	Direct ndirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Pric	e	Transa	nsaction(s) etr. 3 and 4)			(111501.4)
Common Stock 03/27/20)19			S ⁽¹⁾		2,700	D	\$10).72 ⁽²⁾	2,8	305,116])	
Common Stock 03/28/20					2019	019			S ⁽¹⁾		1,300	D	\$	11 ⁽³⁾	2,8	2,803,816)	
Common Stock 03/29/20					2018	018			S ⁽¹⁾		4,815	D	\$10).88(4)	2,7	2,799,001)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execut ecurity or Exercise (Month/Day/Year) if any				4. Transa Code (I 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Deri Seci (Insi	rice of vative urity rr. 5)	9. Number o derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dire or I (I) (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercis	able	Expiration Date		Amoun or Numbe of Shares								

Explanation of Responses:

- 1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
- 2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.60 to \$10.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.695 to \$11.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.60 to \$11.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in

Remarks:

/s/ Mark Ballantyne, Attorney-03/29/2019 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.